← Evidence library

BIB_178

Dummer R et al. Encorafenib + Binimetinib (COLUMBUS). Lancet Oncology 2018;19(5):603–615. PMID 29602646. PFS ~14 months; ORR ~64%; OS ~33 months. Better tolerated than dabra+tram. [Tasks: 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

18

Identifiers

PMID:29602646

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_178/findings.md (research corpus). This page is a short context summary — not individualised medical advice.